- Home
- GENK vs INTS Comparison
GENK vs INTS Comparison
Compare GENK & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | INTS |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3M | 24.0M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | GENK | INTS |
|---|---|---|
| Price | $2.41 | $0.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $7.00 | $4.33 |
| AVG Volume (30 Days) | 46.0K | ★ 3.2M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $217,449,000.00 | N/A |
| Revenue This Year | $10.35 | N/A |
| Revenue Next Year | $14.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.36 | N/A |
| 52 Week Low | $2.20 | $0.19 |
| 52 Week High | $7.87 | $3.17 |
Technical Indicators
Market Signals| Indicator | GENK | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 48.20 | 45.52 |
| Support Level | $2.21 | $0.37 |
| Resistance Level | $2.50 | $0.43 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 70.00 | 13.19 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About INTS Intensity Therapeutics Inc.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.